Quantcast
Channel: Endpoints News

Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks...

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with the Murdoch Children's Research Institute in Australia. The California...

View Article


Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Pfizer is set to enter the heated VEGF bispecific arena. Much like its peers, the New York drug giant is doing so by going to China in the battle for one of oncology's hottest classes ...

View Article


Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Biotech execs don’t quite know what to make of the new FDA chief. There’s been plenty of head-shaking about the controversial provocateur he named to run CBER. Robert F. Kennedy Jr. at ...

View Article

At-home screening startup Reperio Health raises $14M

Telehealth is becoming more comprehensive than a quick online visit. Portland, OR-based Reperio Health got its start in 2020 selling at-home testing kits for employers and health plans, but this year...

View Article

Optura raises $6.5M to help evaluate healthcare AI programs

Healthcare is figuring out what AI to use in a crowded market. Optura says it can help tell you if what you are trying is worth it. The startup, offering a system designed to analyze ...

View Article


Weight loss startup Calibrate replaces CEO in leadership shakeup 

Calibrate has replaced its CEO and made several other executive changes, Endpoints News has learned, the latest leadership reset at the once high-flying weight loss company. Rob Rebak, a veteran CEO of...

View Article

Trump administration reveals 'most favored nation' drug price country targets

The Department of Health and Human Services provided the first details for how it plans to tie US drug prices to rates paid in similarly developed countries as part of President Donald Trump’s most...

View Article

SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff

Plus, news about Beckley Psytech, Regenxbio, Blueprint Medicines, VantAI, NovelMed and Bayer: 💰 SV Health closes second dementia fund: The London-based biotech investment firm closed its second...

View Article


Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with...

Tourmaline Bio's experimental drug for atherosclerotic heart disease reduced markers of inflammation in the blood in a mid-stage study. The company must now show the drug cuts key events such as heart...

View Article


Future Covid vaccine approvals may narrow to older adults, high-risk people

FDA chief Marty Makary and new CBER Director Vinay Prasad said that future Covid-19 vaccine approvals will focus on adults over 65 and high-risk people 6 months to 64 years old, aligning US policy with...

View Article

RFK Jr. spars with senators over HHS budget and research cuts

Senate Democrats grilled HHS Secretary Robert F. Kennedy Jr. on Tuesday over gaps in his budget and funding cuts that have halted or eliminated key clinical research. For the most part, Kennedy pleaded...

View Article

CRISPR Therapeutics partners with siRNA company, showing that gene editing...

The gene editing company CRISPR Therapeutics struck a deal worth $95 million upfront with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA drug for blood...

View Article

Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US patient population for a Columvi label expansion. In the afternoon session,...

View Article


Vinay Prasad makes first major imprint on FDA with new vaccine policy

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines that he feels will counteract existing “dogma.”...

View Article

UK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates

The "healthy lifespan" space is attracting more dollars. Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic. The drug development startup,...

View Article


Reproductive health biotech ReproNovo closes $65M Series A

A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs. ReproNovo announced the close of its Series A round on Wednesday. CEO Jean Marie Duvall...

View Article

Altos Labs buys anti-aging startup Dorian Therapeutics

Altos Labs, the massive but still relatively secretive $3 billion biotech, has forged a small acquisition of a startup seeking to reverse aging. Altos, led by industry stalwarts Hal Barron and Hans ...

View Article


How PureTech’s lung fibrosis drug stacks up against the competition

PureTech Health’s tweaked form of Roche’s lung fibrosis drug Esbriet slowed lung function decline by a greater degree than Esbriet itself, with comparable safety, the company said Tuesday. On a cross ...

View Article

Genentech expands partnership with molecular glue biotech Orionis

Roche’s subsidiary Genentech is signing a second deal with Orionis Biosciences to expand its search through the world of protein interactions in hopes of developing new cancer drugs. The two companies...

View Article

Shutting down a dementia care startup

View Article

Researchers reveal mixed results from vaccine for cocaine addiction

Scientists from Weill Cornell Medicine in New York have announced the results from a long-awaited but small study of a vaccine designed to soak up cocaine molecules and help people addicted to the...

View Article


Moderna pulls application for Covid-flu shot; Another IPO in Hong Kong

Plus, news about Genfit, Ipsen, Accropeutics, Merck KGaA, Alumis and Acelyrin: Moderna pulls BLA for its Covid-flu shot: The company suggested on its most recent earnings call earlier this month that...

View Article


Biotech downturn exposes startups to big lease liabilities

For some biotechs, the office is a place where scientists gather and pipelines advance. For others, it’s a boat anchor dragging them to the bottom of the sea. Four years into the biotech downturn, some...

View Article

BioNTech invests £1B in growing UK footprint under expanded pact with government

BioNTech is spending up to £1 billion over the next ten years to boost its R&D activities in the UK as part of an enhanced agreement with the UK government. The government is supplying BioNTech ...

View Article